drugset / Trial / NCT06420154
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
Phase 0
Not yet recruiting
9 enrolled
First Affiliated Hospital of Wenzhou Medical University
Shanghai First Song Therapeutics Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of anti- CD19-CAR-T cells in the relapse or refractory autoimmune diseases.
Timeline
- Start
- 2024-05-27
- Primary completion
- 2027-05-27
- Completion
- 2027-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-T cells | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | anti-CD19 CAR-T cells | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | anti-CD19 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |